Wuhan YZY Biopharma Co (HKSE:02496) Change In Receivables : HK$0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co Change In Receivables?

Wuhan YZY Biopharma Co's change in receivables for the quarter that ended in Dec. 2024 was HK$0.0 Mil. It means Wuhan YZY Biopharma Co's Accounts Receivable stayed the same from Jun. 2024 to Dec. 2024 .

Wuhan YZY Biopharma Co's change in receivables for the fiscal year that ended in Dec. 2024 was HK$17.0 Mil. It means Wuhan YZY Biopharma Co's Accounts Receivable declined by HK$17.0 Mil from Dec. 2023 to Dec. 2024 .

Wuhan YZY Biopharma Co's Accounts Receivable for the quarter that ended in Dec. 2024 was HK$54.6 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Wuhan YZY Biopharma Co's Days Sales Outstanding for the six months ended in Dec. 2024 was 86.51.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Wuhan YZY Biopharma Co's liquidation value for the six months ended in Dec. 2024 was HK$-75.3 Mil.

Wuhan YZY Biopharma Co Change In Receivables Historical Data

The historical data trend for Wuhan YZY Biopharma Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co Change In Receivables Chart

Wuhan YZY Biopharma Co Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Change In Receivables

-7.44

5.75

-8.61

17.03

Wuhan YZY Biopharma Co Semi-Annual Data
	Dec21	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

Wuhan YZY Biopharma Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

Wuhan YZY Biopharma Co (HKSE:02496) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Wuhan YZY Biopharma Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	54.567	/	115.109	*	91
=	86.51

2. In Ben Graham's calculation of liquidation value, Wuhan YZY Biopharma Co's accounts receivable are only considered to be worth 75% of book value:

Wuhan YZY Biopharma Co's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	134.82	-	253.367	+	0.75 * 54.567	+	0.5 * 4.548
=	-75.3

Wuhan YZY Biopharma Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan YZY Biopharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN

Website

https://en.yzybio.com

Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing a new class of medicines in respect to anti-tumor bispecific antibody. It generates the majority of its revenue from PRC.

Executives

Wen Zhicheng	2201 Interest of corporation controlled by you
Guo Hong Wei
Dragon Merit Holdings Limited	2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si	2101 Beneficial owner
Cspc Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
Robust Sun Holdings Limited	2201 Interest of corporation controlled by you
Wang Hongjie	2201 Interest of corporation controlled by you
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si	2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si	2201 Interest of corporation controlled by you
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
Cdh 2018 Vgc Investment Fund, L.p.	2201 Interest of corporation controlled by you
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng

Wuhan YZY Biopharma Co Headlines

No Headlines